Top Back to top

Physicians Webinars

Upcoming webinars from EBMT

Conditioning prior to allogeneic transplantation: myeloablative, non-myeloablative or reduced-intensity?

The webinar has been postponed due to unforeseen circumstances.

Register to this live webinar (date to be confirmed), click HERE and complete the webform.

The webinar will be hosted by Dr Didier Blaise and moderated by Dr Nicolaus Kröger.

This webinar will review the advancements achieved during this period of time and will focus on how to use them for clinical practice.

Learning objectives:

  • To understand changes in CDT over the years
  • To improve transplant outcome
  • To choose adequate CDT for a given patient
  • To elaborate strategies concerning CDT in a transplant centre

This webinar is accredited by the EBAH-CME credits system.

Past webinars

  

Adoptive transfer of virus-specific T-cells (VST)

The webinar was organized by the Paediatric Diseases Working Party (PDWP). It was hosted by Dr Tobias Feuchtinger and moderated by Dr Peter Lang.

We discussed the current situation of a clinician treating a patient with refractory virus infection after stem cell transplantation, including review of the literature, technical possibilities of adoptive T cell transfer, the level of evidence using antigen specific T cells for treatment, current indications, clinical management and follow up.

This webinar was accredited by the EBAH-CME credits system.

How to treat acute Graft-versus-Host Disease in 2021 (PDWP)

The webinar was organized by the Paediatric Diseases Working Party (PDWP). It was hosted by Dr Anita Lawitschka and moderated by Dr Hildegard Greinix.

The learning objectives were:

  • How diagnosis and treatment of aGVHD has progressed.
  • To learn a risk-based approach.
  • To have a better understanding of the GVHD complexities with the emphasis on the counterbalance of immunosuppression and the risks of relapse and infectious complications.

This webinar was accredited by the EBAH-CME credits system.

Cellular therapy in inborn errors of metabolism: indications and perspectives (IEWP)

The webinar was organized by the Inborn Errors Working Party (IEWP).

This EBMT IEWP webinar is for transplant and metabolic/genetic physicians, and aims to provide up-to-date talks on allogeneic cell therapy and stem cell gene therapies in lysosomal storage diseases and other metabolic diseases.

Dr Rob Wynn from Manchester gave the allogeneic transplant summary talk, and included practical discussion of cord blood transplant technology in these disorders, and included discussions of newer and challenging indications including Wolman disease and MNGIE.

Dr Maria Ester Bernardo from Milan reviewed gene therapies in metabolic diseases, including MLD, MPSI and other MPS disorders. She anticipated the change from allogeneic to autologous transplant in these illnesses, and the challenges associated with this transition.

Speaker panel:

Moderators:

  • Bénédicte Neven, MD, PhD. Necker Children Hospital, Université de Paris, Paris, France.
  • Michael Albert, MD. Professor. Head, Pediatric SCT Program. Dr. von Hauner Children's Hospital, LMU. Munich. Germany

Speakers:

  • Rob Wynn. Honorary Clinical Professor of Paediatric Haematology and Cellular Therapy. Director of the Bone Marrow Transplant Unit. Royal Manchester Children’s Hospital. United Kingdom
  • Maria Ester Bernardo. Associate Professor of Pediatrics "Vita-Salute San Raffaele" University Medical School. San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET). Pediatric Immunohematology. San Raffaele Scientific Institute. Milano, Italy.

This webinar was accredited by the EBAH-CME credits system.

Autologous SCT for multiple myeloma: a journey from past to future

The webinar was hosted by Dr Mohamad Mohty and moderated by Dr Stefan Schönland.

This webinar aims to address some of these important questions with a learning goal to allow to be acquainted with the most recent and latest available data.

The video will be available for EBMT members on the e-learning platform.

Update on diagnostic and treatment of severe combined immunodeficiencies (IEWP)

The webinar was organized by the Inborn Errors Working Party (IEWP).

Programme:
  • New born screening in SCID (Marjam van der Burg)
  • HSCT approaches in SCID (Manfred Hoenig)
  • Gene therapy in SCID (Claire Booth)
  • Q&A (Moderated by: Bénédicte Neven and Arjan Lankaster)
Learning objectives:
  • To learn about neonatal screening of SCID 
  • How to manage transplant in this disease especially in the future with implementation of newborn screening?
  • What is the place of gene therapy?
Speaker panel:

Moderators:

  • Bénédicte Neven, MD, PhD. Necker Children Hospital, Université de Paris, Paris, France.
  • Arjan C Lankester, professor of Paediatrics and Stem Cell Transplantation. Willem-Alexander Children’s Hospital. Paediatric Stem Cell Transplantation Program. Leiden University Medical Center. The Netherlands.

Speakers:

  • Mirjam van der Burg, PhD. Associate Professor Primary Immunodeficiencies. Dept. of Pediatrics, Laboratory for Pediatric Immunology. Willem Alexander Children’s Hospital, Leiden University Medical Center.
  • Manfred Hönig. Assistant Professor Dr. University Medical Center Ulm University, Department of Pediatrics, Ulm, Germany.
  • Claire Booth. Associate Professor in Gene Therapy, UCL GOS Institute of Child Health. Consultant in Paediatric Immunology, Great Ormond Street Hospital. UK.

The video will be available for EBMT members on the e-learning platform.

How to treat chronic Graft-versus-Host Disease in 2021 (PDWP)

The webinar was organized by the Paediatric Diseases Working Party (PDWP). It was hosted by Dr Daniel Wolff and moderated by Dr Jörg Halter.

This recorded webinar gives an overview on First- and Second line treatment principles and options of chronic GVHD. 

Thrombotic Microangiopathy –associated with HSCT (TA-TMA)

The webinar was hosted by Dr Enric Carreras and moderated by Dr Olaf Penack.

This seminar aims to transmit to the audience the basic knowledge about transplant associated thrombotic microangiopathy, from its pathogenesis to its diagnosis, differential diagnosis, management and treatment.

Learning objective:

  • The basic objective is that the audience learns to suspect and diagnose as soon as possible this complication.

The video will be available for EBMT members on the e-learning platform.

Haplo-Identical HSCT, Methods and Practices Around the Globe (EBMT&WBMT)

This webinar, jointly organized by EBMT and WBMT, summarized the different platforms developed around the world to perform haploidentical transplants.

Programme:
  • Opening remarks
  • Haploidentical HSCT practice in Europe. Andrea Bacigalupo (Italy) 
  • Haploidentical HSCT practice in Asia. Xiao-Jun Huang (China)
  • Haploidentical HSCT practice in North America. Leo Luznik (USA)
  • Q&A Live Session
Learning objectives:
  • To describe the global transplant rates and trends in haploidentical SCT
  • To summarize the platforms developed in China, Europe and the USA to perform haploidentical SCT
  • To review outcome data in comparison to other donor sources
Speaker panel:

Moderators:

  • Nicolaus Kröger, MD. Professor of Medicine. EBMT President. Director Department of Stem Cell Transplantation. University Hospital Hamburg-Eppendorf. Germany.
  • Univ. Prof. Dr. Hildegard T. Greinix. Head of the Division of Hematology of the Medical University Graz, Austria.

Speakers:

  • Professor Andrea Bacigalupo. Department of Hematology. Fondazione Policlinico Universitario A.Gemelli IRCCS Universita’ Cattolica del Sacro Cuore. Rome, Italy.
  • Xiao-Jun Huang. Professor, Director, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Dr Leo Luznik. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.

Good Practices for evaluating quality, safety and efficacy of novel tissue and cellular therapies and products - EuroGTP II Methodologies and Tools

The webinar aimed to improve the scientific assessment of novel products/processes/clinical indications and associated risks and promote the correct definition of evaluation protocols to guarantee its safe implementation.

Programme:
  • Introduction to EuroGTP methodologies (Richard Lomas)
  • Practical cases (Aurora Vassanelli)
  • Discussion - Q&A - (Moderator: Jaime Tabera)
  • Impact and continuity of EuroGTP II Project– (Rita Piteira)

By the end of this training participants should be able:

  • Correctly assess the novelty of a TCTP.
  • Understand the different risk factors and risk consequences associated with the TE’s activities and clinical application of Substances of Human Origin.
  • Perform objective risk analysis based on the rationale proposed by EuroGTP II – by evaluating the risks resulting from all aspects of T&C supply chain (from donor selection to clinical application) of the final product.
  • Design appropriate studies proportionate to the level of residual/unknown risk to confirm that the TCTP is safe and effective.
  • Understand the value of the Tissue & Cell Database.
Speaker panel:

Moderators:

  • Anne-Marie van Walraven. TRIP office for Hemo and Biovigilance and at Sanquin Blood Supply, currently as privacy coordinator of the the Blood Bank. Netherlands.
  • Jaime Tabera. Operations and Quality Assurance Manager, Barcelona Tissue Bank (BTB) of Banc de Sang I Teixits (BST), Catalonia, Spain

Speakers:

  • Richard Lomas. Senior Clinical Development Scientist, National Health Service - Blood and Transplant (NHSBT), Tissue and Eye Services, UK.
  • Aurora Vassanelli. Medical Director of the Verona Integrated University Hospital, Banca tessuti e Cellule Staminali UOC Medicina Trasfusionale Ospedale Policlinico Borgo Roma, Verona, Italy.
  • Rita Piteira. Project Coordinator, Barcelona Tissue Bank (BTB) of Banc de Sang I Teixits (BST), Catalonia, Spain.

Role of ECP in treatment of GvHD in the Ruxolitinib-era

The webinar was hosted by Dr Hildegard T. Greinix.

Recently, new immunosuppressive drugs have been approved for treatment of acute and chronic GvHD that is a serious complication of allogeneic HCT. Despite this fact, extracorporeal photopheresis remains an important, efficient and safe part of GvHD treatment strategies. This webinar will discuss the role of ECP in the current situation.

Hormonal replacement therapy in iatrogenic gonadal insufficiency after HSCT: practical recommendations (PDWP)

The webinar was organized by the PDWP, hosted by Dr Alessandro Cattoni and moderated by Dr Adriana Balduzzi.

The learning objectives were:

  • ​How to perform a complete assessment of gonadal function in transplanted patients.
  • Learning a “risk-based” approach to assess and follow-up ovarian function after HSCT.
  • Which are the indications of hormonal replacement therapy after HSCT.
  • Management of hormonal replacement therapy: formulations, timing and doses.
  • How to diagnose and manage pre-clinical gonadal impairment.

The video and slides are available for EBMT members on the e-learning platform.

How to transplant patients with Sickle Cell disease in 2021 (PDWP)

The webinar was organized by the PDWP, hosted by Dr Selim Corbacioglu and moderated by Dr Josu De La Fuente.

This recorded webinar will give you a step-by-step approach on how to approach hematopoietic stem cell transplantation and gene editing for sickle cell disease. It will highlight the pitfalls and particularities in the care of these utmost complicated patients as well as the specific transplant-related complications.

The video and slides are available for EBMT members on the e-learning platform.

 

Maintenance therapy after allogeneic SCT in AML

The live webinar was hosted by Dr Andreas Burchert and moderated by Dr Ali Barzabachi.

The learning objectives were:

  • What is the post HSCT standard of care and which patients are of high risk of relapse?
  • What is the available evidence to perform a post HSCT maintenance therapy in AML?
  • What types of treatments are available (targeted vs. non targeted)?
  • What is the achievable benefit vs. risks?
  • What is the future post HSCT maintenance treatment spectrum?

The video and slides are available for EBMT members on the e-learning platform.

Role of ATG/ATLG in stem cell transplantation

The live webinar was hosted by Dr Francesca Bonifazi and moderated by Dr Grzegorz Basak.

The learning objectives were:

  • Mandatoriness of GVHD prevention because of impact of GVHD on survival
  • Literature evidences on ATG/ATLG as GVHD prevention strategy
  • Mechanisms of action of ATG/ATLG
  • Quality of life after ATG/ATLG treatment
  • Open issues to increase outcome and knowledge about dosing and schedule

The video and slides are available for EBMT members on the e-learning platform.

Past workshops

Statistical Course - 2021 Edition

Basic course in the use of statistical methods to analyse stem cell transplantation data.

It had two parts:

  1. Collection of data, simple comparative analyses. Speaker: Richard Szydlo.

The first session covered the following topics:

  • Best data collection practices using Excel and Access
  • Basic descriptive and comparative statistical methods using a live analysis of data (with SPSS)
  • Optimum methods for collecting data that require statistical analysis
  • A review of the most commonly used statistical methods to describe and compare groups
  1. Essential survival analysis methods. Speaker: Antonella Santucci. 

The second session covered the following topics:

  • Interval Time of follow-up and the status variable (censored/event observations)
  • How to collect data 
  • The survival function
  • Kaplan-Meier curves and the log rank test
  • An introduction to Cox proportional hazard model
  • Demonstrative exercises will be done by  using SPSS vers.25.
IMPORTANT INFORMATION:

One week before the event, all participants received access to on-demand content regarding theoretical information of “Essential survival analysis methods”. During the live event, more practical aspects were explained and there was time for questions and answers.

On-demand material and attendance certificate is available to consult for registered participants on the e-learning platform. 

Speakers:

  • Dr Richard Szydlo, Medical Statistician, Department of Haematology, Imperial College, London, UK.
  • Dr Antonella SantucciHaemathology Institut University of Study of Perugia.

EBMT Benchmarking: The What, How and When?

The EBMT Clinical Outcomes Group (COG) has developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. In November 2020, centres received the first data-completeness reports. This webinar will explain the origins and methodology of the model, the centre perspective and the next steps. The webinar will be an opportunity for users to address questions to the expert panel and to give feedback on this first report. This feedback will be taken into account for the next phase of this project.

Learning Objectives:
  • Understand the basis of the benchmarking model

  • Learn to interpret the data-completeness report

  • Hear of future plans for the model

Speaker panel:

Chair: 

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.

Speakers: 

  • Prof. Dr. Hein Putter. Biostatistician, Leiden University Medical Center, Leiden, The Netherlands.

  • Riccardo Saccardi, MD. Director, Cell Therapy and Transfusion Medicine Unit. Careggi University Hospital, Firenze, Italy.

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.

Q&A Section: 

  • Prof. Dr. Hein Putter. Biostatistician, Leiden University Medical Center, Leiden, The Netherlands.

  • Riccardo Saccardi, MD. Director, Cell Therapy and Transfusion Medicine Unit. Careggi University Hospital, Firenze, Italy.

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.
  • Dirk-Jan Eikema. Biostatistician specialized in survival analysis. EBMT.

  • Isabel Sánchez-Ortega. Medical Officer. EBMT

Sponsorship

There are various opportunities to support the EBMT Educational Webinars. For more information, please send an email to fundraising@ebmt.org